1. Home
  2. KELYB vs JANX Comparison

KELYB vs JANX Comparison

Compare KELYB & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kelly Services Inc. Class B

KELYB

Kelly Services Inc. Class B

HOLD

Current Price

$23.27

Market Cap

814.8M

ML Signal

HOLD

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$19.86

Market Cap

975.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KELYB
JANX
Founded
1946
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
814.8M
975.7M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
KELYB
JANX
Price
$23.27
$19.86
Analyst Decision
Buy
Analyst Count
0
13
Target Price
N/A
$47.00
AVG Volume (30 Days)
633.0
748.7K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
1.95%
N/A
EPS Growth
N/A
N/A
EPS
0.15
N/A
Revenue
$5,355,600,000.00
$10,000,000.00
Revenue This Year
$0.72
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$155.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.38
$12.12
52 Week High
$125.00
$35.34

Technical Indicators

Market Signals
Indicator
KELYB
JANX
Relative Strength Index (RSI) 52.73 71.63
Support Level $21.49 $13.00
Resistance Level $24.78 $35.34
Average True Range (ATR) 0.70 0.71
MACD -0.08 0.16
Stochastic Oscillator 68.54 90.42

Price Performance

Historical Comparison
KELYB
JANX

About KELYB Kelly Services Inc. Class B

Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: